SOURCE: PHT Corporation

March 05, 2008 09:00 ET

PHT's Revolutionary SitePad™ Tablet Forever Changes Site-Based Clinical Data Capture

Virtual Launch on March 28 Will Demonstrate How the Breakthrough Mobile Technology Ensures Complete, Timely Questionnaires

BOSTON, MA--(Marketwire - March 5, 2008) - PHT Corporation is pleased to introduce its revolutionary SitePad™ Tablet, a breakthrough eSource technology answer to intense market demand for trustworthy site-based PRO data. The SitePad Tablet is a user-friendly and large-screen mobile device which guarantees complete and timely questionnaire data from subjects and clinicians at sites around the world. The SitePad Tablet delivers the voice of the patient to researchers and regulators for proof of safety and efficacy. PHT will host a virtual worldwide launch of the SitePad Tablet on Friday, March 28, from 12:00-1:00pm (Eastern), with all attendees eligible to win a Samsung Q1 Ultra Mobile PC (UMPC) -- registration is available at: www.phtcorp.com/Tablet.

"The SitePad Tablet looks great, and fills a need the industry has had for quite some time," said Joachim Löwin, Clinical Information Science Leader at AstraZeneca, following a sneak preview of the device. "For years I have emphasized the importance of capturing unfiltered and unbiased PRO responses directly from patients rather than relying on investigators to try to explain how the patients feel. The fact that a good enough device hadn't been available forced us to work with other solutions and even revert to paper. I am excited about PHT's SitePad Tablet because it offers a combination of a large screen, allowing for long questions, and an easy-to-use interface."

Industry research indicates 50-60% of all clinical studies capture health-related quality of life data, a figure which is rising due to recent FDA emphasis on involving patient input in clinical research. These questionnaires are currently conducted on unreliable and error-prone paper formats. The SitePad Tablet features the following controls and conveniences to guarantee timely and complete questionnaires:

--  Large, high-resolution 7" LCD touchscreen which supports complex
    questionnaires, numerous response options, and a 10-cm Visual Analog Scale
--  Intuitive user interface with convenient fingertip data entry
--  Automatic symptom scoring and eligibility calculations
--  Protocol-specific work flows which present appropriate questionnaires
    to sites and patients for timely completion
--  High-speed Ethernet data transmission of stored reports to secure
    central servers
--  Real-time access to all data and summaries in PHT's online
    StudyWorks™ portal, including questionnaire completion and visit reports
    

"Since the project's launch over one year ago, we've developed the SitePad Tablet with constant input from study coordinators and other site personnel to ensure it address their needs with powerful tools, yet remains remarkably easy to use," said Ian McLeod, PHT's Vice President of Development. "We chose the Samsung Q1 UMPC device due to its ergonomic form factor, attractive bright display, Microsoft Windows® Operating System and reasonable price point."

The SitePad Tablet is part of PHT's proven and regulatory-compliant ePRO Product Suite. It is ideal for trials that include a site-based PRO component, such as oncology, pain, disorders of the CNS, Alzheimer's, psychiatric indications, registry studies and Phase IV programs.

"We are excited to deliver the SitePad Tablet to solve the problem of incomplete and unreliable questionnaire data," said Phil Lee, PHT President and CEO. "With the SitePad Tablet we've opened the door for study teams to experience firsthand how a well-designed ePRO system transforms the quality and efficiency of global clinical research programs."

"I believe the SitePad Tablet is something that can help our entire industry, and patients, as well," added Mr. Löwin.

About PHT Corporation

PHT is the market-leading provider of electronic patient reported outcome (ePRO) solutions used in more than 345 clinical trials by 90 biopharmaceutical clients around the world. The company's proven LogPad® and SitePad® Tablet deliver the voice of the patient -- directly and without distortion -- with reliable and timely self-reported data. Patient experiences captured firsthand by PHT's ePRO Product Suite have been used successfully in at least nine NDA submissions, with five known approvals, to date. To learn more about how study sponsors worldwide are using ePRO to improve data quality, conduct smaller trials, and manage patient safety, enrollment and compliance in real time, visit www.phtcorp.com.

PHT, LogPad, SitePad and StudyWorks are among the registered trademarks and trademarks of PHT Corporation. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

Contact Information


  • Contact:
    Kris Sarajian
    for PHT Corporation
    Email Contact
    617-973-1706

Multimedia